Positive interim data on birinapant in combination with Keytruda®
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced safety and efficacy data following an interim analysis of phase I data from the ongoing phase I/II study of birinapant in combination with MSD’s anti-PD-1 therapy, Keytruda® (pembrolizumab), in patients with advanced solid tumors who have exhausted available treatment options. No dose-limiting toxicity has been observed in the first three groups of patients, and the dose escalation has been continued to the highest planned dose level in the study. One of the 12 patients in this interim analysis has had a confirmed